Health · 2 views
Molecular imaging demonstrates promise for predicting complete pathologic response in HER2-positive breast cancer
Molecular imaging with ⁶⁸Ga-HER2 PET/CT may provide an early, targeted measure of how well treatment is working in patients with HER2-positive breast cancer.
Summary
Molecular imaging with ⁶⁸Ga-HER2 PET/CT may provide an early, targeted measure of how well treatment is working in patients with HER2-positive breast cancer. According to new research published in the October issue of The Journal of Nuclear Medicine , ⁶⁸Ga-HER2 PET/CT can detect changes in HER2-positive breast cancer after only two cycles of neoadjuvant treatment, giving physicians information that could support earlier discussions about subsequent treatment and surgical planning.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
More from Health
Continue reading recent Health coverage
- Menopause hormone therapy gets stronger endorsement from OB-GYNs in expanded guidelineContinue reading
- Persistent gaps remain in hearing aid coverage, especially for older and lower-income adults, study findsContinue reading
- First At-Home Thyroid Eye Disease Shot ApprovedContinue reading
- Intermittent hemodialysis not noninferior to continuous renal-replacement therapyContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow